ENHANZE Drug Delivery Technology

Convert IV to SC

ENHANZE® offers the potential for transformative experiences with biologics administration.

Potential to reduce C_max-driven toxicities

The inherent reduction in C_max achieved with SC administration compared to IV has the potential to reduce C_max-driven toxicities.¹

Reduced infusion-related reactions (IRRs)

3- to 5-fold reduction in Infusion Related Reactions/Systemic Related Reactions has been observed for formulations with daratumumab, IgG, and pertuzumab/trastuzumab when administered SC with rHuPH20 compared to IV.^2,3,4

Reduced treatment and administration time

SC administration with rHuPH20 reduced overall treatment time for rituximab from averages of 264 to 70 minutes, and administration time from averages of about 223 to 49 minutes (~5-minute SC injection) compared to IV.⁵

Increased patient preference

In clinical trials that included evalution of patient experience, 86% (199/231) of trastuzumab, 85% (136/160) of pertuzumab/trastuzumab, and 77% (477/620) of rituximab, patients preferred SC administration with rHuPH20 over IV.^3,6,7

Combined two therapies in a single injection

Pertuzumab, trastuzumab, and rHuPH20 are formulated together and marketed as a single 10 or 15 mL product for SC injection.³

Potential Administrative Benefits for Existing SC Therapies

ENHANZE® has created expanded opportunities for SC dosing regimens.

ENHANZE^® Solutions and Potential Benefits

Convert IV to SC

Potential to reduce C_max-driven toxicities

Reduced infusion-related reactions (IRRs)

Reduced treatment and administration time

Increased patient preference

Combined two therapies in a single injection

Potential Administrative Benefits for Existing SC Therapies

Enabled large volume in single injection

Extended SC dosing interval for fewer and less frequent injections

Reduced treatment and administration time

Increased bioavailability

ENHANZE® Solutions and Potential Benefits

Convert IV to SC

Potential to reduce Cmax-driven toxicities

Reduced infusion-related reactions (IRRs)

Reduced treatment and administration time

Increased patient preference

Combined two therapies in a single injection

Potential Administrative Benefits for Existing SC Therapies

Enabled large volume in single injection

Extended SC dosing interval for fewer and less frequent injections

Reduced treatment and administration time

Increased bioavailability

ENHANZE^® Solutions and Potential Benefits

Potential to reduce C_max-driven toxicities